Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03 2024 - 7:00AM
Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic
medicine company dedicated to pioneering treatments for genetically
defined cardiovascular diseases and APOE4-associated Alzheimer's
disease, today announced that R. Nolan Townsend, Chief Executive
Officer of Lexeo Therapeutics, will present at the 42nd Annual J.P.
Morgan Healthcare Conference on Wednesday, January 10, 2024 at 8:15
AM PT in San Francisco, California.
The event will be webcast live under the News & Events tab
in the Investors section of the Company’s website. A replay of the
webcast will be available after the conclusion of the live
presentation.
About Lexeo TherapeuticsLexeo Therapeutics is a
New York City-based, clinical stage genetic medicine company
dedicated to transforming healthcare by applying pioneering science
to fundamentally change how genetically defined cardiovascular
diseases and APOE4-associated Alzheimer’s disease are treated.
Using a stepwise development approach, Lexeo is leveraging early
proof-of-concept functional and biomarker data to advance a
pipeline of cardiovascular and APOE4-associated Alzheimer’s disease
programs.
Media Response:Janine Bogris(201)
245-6838janine.bogris@canalecomm.com
Investor Response:Laurence Watts(619)
916-7620laurence@gilmartinir.com
Lexeo Therapeutics (NASDAQ:LXEO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexeo Therapeutics (NASDAQ:LXEO)
Historical Stock Chart
From Jul 2023 to Jul 2024